All In Biotech

Drug Trial Radar · NCT00003934

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia

Last checked: Nov 20, 2026Latest source record: Jun 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Actual

Start

Jun 1999

Primary completion

Nov 2006

Sponsor

Sponsor type
NIH
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia.

Conditions

  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
  • Adult Acute Promyelocytic Leukemia (M3)
  • Childhood Acute Promyelocytic Leukemia (M3)
  • Untreated Adult Acute Myeloid Leukemia
  • Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions

  • tretinoinDrug

    Given orally

  • daunorubicin hydrochlorideDrug

    Given IV

  • cytarabineDrug

    Given IV

  • mercaptopurineDrug

    Given IV

  • methotrexateDrug

    Given IV

  • arsenic trioxideDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response ratesTime frame: Up to 10 years
  2. Distributions of event-free survivalTime frame: Up to 10 years
  3. Disease-free survivalTime frame: Time from the date of the maintenance randomization to relapse or death, assessed up to 10 years
  4. SurvivalTime frame: Up to 10 years
  5. Toxicities for the various therapies graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0Time frame: Up to 30 days after last dose of study treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer and Leukemia Group B

    Chicago, Illinois

  • Comprehensive Cancer Center of Wake Forest University

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.